Literature DB >> 17462498

Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation.

Karina L McQueen1, Kristel M Dorighi, Lisbeth A Guethlein, Ruby Wong, Bharati Sanjanwala, Peter Parham.   

Abstract

The influence of donor and recipient killer immunoglobulin-like receptor (KIR) genotype on the outcome of hematopoietic cell transplantation between human leukocyte antigen (HLA)-matched siblings was investigated. Transplants were divided into four groups according to the combination of group A and B KIR haplotypes in the transplant donor and recipient. Overall survival of myeloid patients varied with KIR genotype combination. Best survival was associated with the donor lacking and the recipient having group B KIR haplotypes; poorest survival was associated with the donor having and the recipient lacking group B KIR haplotypes. The latter combination was also associated with increased relapse and acute graft-versus-host disease (GVHD). However, its detrimental effects were seen only for transplants where the recipient and donor were homozygous for the C1 KIR ligand and therefore lacked the C2 ligand. Presence of the Bw4 ligand was also associated with increased acute GVHD. In contrast presence of both KIR3DL1 and its cognate Bw4 ligand was associated with decreased nonrelapse mortality. Analysis of the KIR genes individually revealed KIR2DS3 as a protective factor for chronic GVHD. The results suggest how simple assessments of KIR genotype might inform the selection of donors for hematopoietic cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17462498      PMCID: PMC1937576          DOI: 10.1016/j.humimm.2007.01.019

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  49 in total

1.  Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer.

Authors:  N Wagtmann; S Rajagopalan; C C Winter; M Peruzzi; E O Long
Journal:  Immunity       Date:  1995-12       Impact factor: 31.745

2.  Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains.

Authors:  N Wagtmann; R Biassoni; C Cantoni; S Verdiani; M S Malnati; M Vitale; C Bottino; L Moretta; A Moretta; E O Long
Journal:  Immunity       Date:  1995-05       Impact factor: 31.745

3.  Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells.

Authors:  M Colonna; J Samaridis
Journal:  Science       Date:  1995-04-21       Impact factor: 47.728

4.  HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells.

Authors:  M Colonna; G Borsellino; M Falco; G B Ferrara; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

5.  A human killer inhibitory receptor specific for HLA-A1,2.

Authors:  C Döhring; D Scheidegger; J Samaridis; M Cella; M Colonna
Journal:  J Immunol       Date:  1996-05-01       Impact factor: 5.422

6.  A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes.

Authors:  C C Winter; E O Long
Journal:  J Immunol       Date:  1997-05-01       Impact factor: 5.422

7.  Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes.

Authors:  A D'Andrea; C Chang; K Franz-Bacon; T McClanahan; J H Phillips; L L Lanier
Journal:  J Immunol       Date:  1995-09-01       Impact factor: 5.422

8.  Different and divergent regulation of the KIR2DL4 and KIR3DL1 promoters.

Authors:  C Andrew Stewart; Jeroen Van Bergen; John Trowsdale
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

9.  The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor.

Authors:  J E Gumperz; V Litwin; J H Phillips; L L Lanier; P Parham
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

10.  Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success.

Authors:  Susan E Hiby; James J Walker; Kevin M O'shaughnessy; Christopher W G Redman; Mary Carrington; John Trowsdale; Ashley Moffett
Journal:  J Exp Med       Date:  2004-10-11       Impact factor: 14.307

View more
  44 in total

1.  Interaction between immunoglobulin allotypes and NK receptor genes in diabetes post-hepatitis C virus infection.

Authors:  Julio Granados-Montiel; Joaquin Zúñiga; Jose Azocar; Edmond J Feris; Daniel Terreros; Charles E Larsen; Olga P Clavijo; Alfredo Cruz-Lagunas; Derek Middleton; Chester A Alper; Janardan P Pandey; Edmond J Yunis
Journal:  Immunobiology       Date:  2010-11-05       Impact factor: 3.144

Review 2.  Genetics of graft-versus-host disease: the major histocompatibility complex.

Authors:  Effie W Petersdorf
Journal:  Blood Rev       Date:  2012-11-20       Impact factor: 8.250

Review 3.  Clinical utility of natural killer cells in cancer therapy and transplantation.

Authors:  David A Knorr; Veronika Bachanova; Michael R Verneris; Jeffrey S Miller
Journal:  Semin Immunol       Date:  2014-03-05       Impact factor: 11.130

Review 4.  Targeting natural killer cells and natural killer T cells in cancer.

Authors:  Eric Vivier; Sophie Ugolini; Didier Blaise; Christian Chabannon; Laurent Brossay
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

Review 5.  Natural killer cell receptors: alterations and therapeutic targeting in malignancies.

Authors:  Gordana Konjević; Ana Vuletić; Katarina Mirjačić Martinović
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

6.  Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantation.

Authors:  Rafijul Bari; Piya Rujkijyanont; Erin Sullivan; Guolian Kang; Victoria Turner; Kwan Gan; Wing Leung
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

7.  Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.

Authors:  Heather J Symons; M Sue Leffell; Nancy D Rossiter; Marianna Zahurak; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-02       Impact factor: 5.742

8.  Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia.

Authors:  Vanderson Rocha; Annalisa Ruggeri; Stephen Spellman; Tao Wang; Ronald Sobecks; Franco Locatelli; Medhat Askar; Gerard Michel; William Arcese; Anna Paola Iori; Duncan Purtill; Robert Danby; Guillermo F Sanz; Eliane Gluckman; Mary Eapen
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-16       Impact factor: 5.742

9.  Use of natural killer cells as immunotherapy for leukaemia.

Authors:  Bartosz Grzywacz; Jeffrey S Miller; Michael R Verneris
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

10.  KIR gene content diversity in four Iranian populations.

Authors:  Elham Ashouri; Shirin Farjadian; Elaine F Reed; Abbas Ghaderi; Raja Rajalingam
Journal:  Immunogenetics       Date:  2009-06-12       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.